| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2014: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Outline of Final Research Achievements |
Using RAPDx for refractory optic nerve disease, objective and quantitative therapeutic evaluation of transcorneal electrical stimulation therapy (TES) was performed. The subjects were 5 cases of traumatic optic neuropathy and 9 cases of ischemic optic neuropathy. The amplitude score (AS) and latency score (LS) of RAPDx were measured before treatment and one month after the end of treatment, and statistical analysis was performed using t test for both groups AS and LS before and after treatment. The results showed that there was no statistically significant difference between AS and LS before and after treatment in both groups. For each case, there was one case with traumatic optic nerve cases and two cases with ischemic optic neuropathy in which AS was clearly reduced. It is suggested that TES may be effective even in a few cases, even in objective evaluation.
|
